SOX4

Across TCGA pan-cancer cohorts, SOX4 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SOX4 data layer compared with 25 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SOX4 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated SOX4 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

PDAC, LSCC, and LUAD are the cancer types where SOX4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	II,III,IV	0.371	0.660	.010	8	view →
LSCC	OS	Quartile	All	0.947	0.650	.015	5	view →
LUAD	DFS	Median	All	0.491	0.738	.016	2	view →
HNSC	OS	Quartile	III,IV	0.409	1.000	.040	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SOX4–PDAC (OS)

Open the PDAC breakdown →